Toggle Nav
Close
  • Menu
  • Setting

Recombinant Rat VEGF164, Yeast

Catalog No.
P1205
Vascular endothelial growth factor (VEGF or VEGF-A)/vascular permeability factor (VPF), is an important signaling protein as a potent mediator of both angiogenesis and vasculogenesis
Grouped product items
SizePriceStock Qty
10ug
$246.00
Ship with 5-10 days
100ug
$1,057.00
Ship with 5-10 days
500ug
$2,371.00
Ship with 5-10 days
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Vascular endothelial growth factor (VEGF or VEGF-A)/vascular permeability factor (VPF), is an important signaling protein as a potent mediator of both angiogenesis and vasculogenesis. It is a member of the platelet-derived growth factor (PDGF) family, and characterized by a cysteine-knot structure and disulfide-linked homodimer. Alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) have been identified in humans, with 120, 164 and 188 aa isoforms found in mouse. VEGF binds the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells. VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells. In adults, VEGF functions mainly in wound healing and the female reproductive cycle. Pathologically, it is involved in tumor angiogenesis and vascular leakage. Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus.

Description

Gene ID

 

Accession #

 

Alternate Names

 

Source

Yeast

M.Wt

Theoretically as a disulfide-linked homodimeric protein, the product consists of two 165 amino acid polypeptide chains. As a result of glycosylation, it migrates to at least two bands with molecular weights ranging from 25.7 kDa in SDS-PAGE under reducing conditions.

AA Sequence

MAPTTEGEQK AHEVVKFMDV YQRSYCRPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCAGC CNDEALECVP TSESNVTMQI MRIKPHQSQH IGEMSFLQHS RCECRPKKDR TKPEKHCEPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR

Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.

1 month, 2 to 8 °C under sterile conditions after reconstitution.

3 months, -20 to -70 °C under sterile conditions after reconstitution.

Formulation

 

Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Biological Activity

Fully biologically active when compared to standard. Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 0.75‑3.75 ng/mL.

Shipping Condition

Gel pack.

Handling

Centrifuge the vial prior to opening.

Usage

For Research Use Only! Not to be used in humans.

Quality Control

Quality Control & DataSheet

View current batch:
    Purity > 95 % by SDS-PAGE and 90% by SEC-HPLC analyses.
    Endotoxin: Less than 0.1 EU/μg of rRtVEGF164, Yeast as determined by LAL method.
  • Datasheet